Scarica l'app Stockscreener
8.31
1.07%
-0.09
Dopo l'orario di chiusura:
8.31
Precedente Chiudi:
$8.40
Aprire:
$8.39
Volume 24 ore:
1.15M
Relative Volume:
0.62
Capitalizzazione di mercato:
$860.23M
Reddito:
-
Utile/perdita netta:
$-135.21M
Rapporto P/E:
-5.8067
EPS:
-1.4311
Flusso di cassa netto:
$-114.35M
1 W Prestazione:
+3.88%
1M Prestazione:
+1.96%
6M Prestazione:
-8.88%
1 anno Prestazione:
-11.69%
Intervallo 1D:
$8.085
$8.49
Intervallo di 1 settimana:
$7.455
$8.50
Portata 52W:
$7.23
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Nome
Oric Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 388-5600
Indirizzo
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
8.31 | 869.55M | 0 | -135.21M | -114.35M | -1.4311 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Piper Sandler | Overweight |
| 2025-11-20 | Iniziato | Evercore ISI | Outperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2024-10-31 | Iniziato | Wells Fargo | Overweight |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-02-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Iniziato | Wedbush | Outperform |
| 2023-03-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Perform |
| 2022-04-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-03-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-13 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Citigroup | Neutral |
| 2020-05-19 | Iniziato | Guggenheim | Buy |
| 2020-05-19 | Iniziato | JP Morgan | Overweight |
| 2020-05-19 | Iniziato | Jefferies | Buy |
Mostra tutto
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
ORIC gains as Stifel resumes at buy on upcoming Pfizer readout - MSN
ORIC Pharmaceuticals (ORIC) Gains on Buy Rating from Stifel Amid Positive Trial Outlook - GuruFocus
ORIC gains as Stifel resumes at Buy on upcoming Pfizer readout - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Oric Pharmaceuticals (ORIC) and Pfizer (PFE) - The Globe and Mail
Buy Rating and $14 Target Set for Oric Pharmaceuticals (ORIC) - GuruFocus
Stifel initiates Oric Pharmaceuticals stock with buy rating By Investing.com - Investing.com Nigeria
Stifel initiates Oric Pharmaceuticals stock with buy rating - Investing.com
ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market - Streetwise Reports
ORIC: Phase III prostate cancer trial set to start, with strong safety and efficacy data and robust cash runway - TradingView
Oric Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
ORIC Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Oric Pharmaceuticals stock edges up 1.60% as company executives join Goldman Sachs healthcare event, oricpharma - Traders Union
H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Clinical-Stage Biopharma Co. Issues New Inducement Stock Options for Growth - Streetwise Reports
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
Oric Pharmaceuticals stock falls 6.48% amid bearish momentum as Oric Pharmaceuticals honors cancer survivors - Traders Union
Oric Pharmaceuticals (ORIC) Sheds 6.5% as Shares Test Key Support LevelsUp Down Volume - newsline.com
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
ORIC Pharmaceuticals grants inducement equity to new hires - scanx.trade
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new ORIC hires receive stock options and RSU awards - Stock Titan
Goldman Sachs Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $15 - Moomoo
Oric Pharmaceuticals stock under sustained selling pressure, trades near new support zone - Traders Union
This ORIC Pharmaceuticals Insider Increased Their Holding In The Last Year - Moomoo
ORIC Pharmaceuticals (ORIC) Stock Analysis Report | Financials & Insights - Benzinga España
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Oncology company ORIC plans June talks at Jefferies, Goldman events - Stock Titan
What's behind the drop in Oric Pharmaceuticals stock today? - MSN
ORIC Stock Chart | ORIC PHARMACEUTICALS INC (NASDAQ:ORIC) - ChartMill
Trading Systems Reacting to (ORIC) Volatility - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.ORIC - ACCESS Newswire
ORIC Q1 2026 Earnings: Narrower-Than-Expected Loss, Pipeline Progress Keeps Focus on Key MilestonesEPS Guidance Update - newsline.com
ORIC Stock Heads Into Weekend as Cancer-Trial Deadline Approaches - Bez Kabli
Cantor Fitzgerald reiterates Overweight on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - PR Newswire
User - The Chronicle-Journal
ORIC Pharmaceuticals stock nosedives 25% after hours: What is going on? - MSN
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance
Viking Global (ORIC) reports 8.26M shares; 2.44M warrant rights disclosed - Stock Titan
Venrock affiliates report 4.2% stake in ORIC (NASDAQ: ORIC) update - Stock Titan
Point72-affiliated filers report 0% ownership in ORIC (ORIC) amendment - Stock Titan
T. Rowe Price holds 5.4% of ORIC (ORIC) — 5.39M shares reported - Stock Titan
Goldman Sachs upgrades ORIC Pharmaceuticals stock rating to buy By Investing.com - Investing.com Canada
Goldman Sachs Upgrades Oric Pharmaceuticals (ORIC) with $15 Pric - GuruFocus
Oric Pharmaceuticals Inc Enozertinib (ORIC-114) Program Update Call Transcript - GuruFocus
Oric Pharmaceuticals faces securities fraud probe after prostate cancer drug update causes 41% stock drop - Pluang
Beyond Meat posts downbeat Q4 results, joins RH, ORIC Pharmaceuticals and other big stocks moving lower in Wednesday's pre-market session - MSN
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - FinancialContent
Pfizer (NYSE: PFE) discloses 3.3% holding in ORIC Pharmaceuticals - Stock Titan
Oric Pharmaceuticals Inc Azioni (ORIC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Oric Pharmaceuticals Inc Azioni (ORIC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Feb 24 '26 |
Sale |
13.51 |
52,000 |
702,686 |
68,148 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):